Bristol-Myers Squibb and Ono Enter into Strategic Agreement Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd . BMS-936558/ONO-4538, a human being anti-PD-1 antibody fully, is an investigational cancers immunotherapy generated under a study collaboration entered into in May 2005 between Ono and Medarex, Inc. When Bristol-Myers Squibb acquired Medarex in 2009 2009, it also acquired Medarex’s privileges to build up and commercialize the anti-PD-1 antibody in THE UNITED STATES. Under the conditions of the contract announced today, Ono will grant Bristol-Myers Squibb exclusive rights to develop and commercialize BMS-936558/ONO-4538 in the rest of the world, except in Japan, Korea and Taiwan where Ono offers retained all rights to develop and commercialize BMS-936558/ONO-4538.

Healthcare reform decreased first one fourth EPS from continuing functions by approximately $0.03 on both a GAAP and non-GAAP basis. Further information are discussed beneath the ‘HEALTHCARE Reform Influence’ section. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and providing innovative medicines that help individuals prevail over serious illnesses. To find out more, please visit.. Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter Bristol-Myers Squibb Organization reported strong sales and earnings growth for the first quarter of 2010.